2.43%XLF 15.10 
10.30%QQQQ 31.32 0.63%
Digg
Del.icio.us
Newsvine 
Facebook
Stumbleupon
NEW YORK - Epix Pharmaceuticals Inc. shares have shed about half their value and are trading at all-time lows after the company stopped development of an experimental depression treatment.
| EPIX | 0.38 |  -0.07 |
The Lexington, Mass., company said its PRX-00023 was not effective in a midstage trial against clinical depression. In September, tests showed the drug was no better than a placebo at treating anxiety.
The stock plunged $1.57, or 51 percent, to $1.51 in afternoon trading, bottoming at $1.48.
Epix shares began trading in March 1997, and had ranged between $2.63 and $7.28 over the past year.
Cowen and Co. analyst Ian Sanderson said the previous trial gave investors reason to hope that PRX-00023 would work as a depression treatment, which built up expectations.
The federal investigation of a fatal Texas bus crash zeroed in Tuesday on foreign-made passenger buses that operate in the U.S. but don't meet mi...
Intimate photos taken by Brad Pitt of girlfriend Angelina Jolie breastfeeding on...
In last week's report, I held out the prospect that the US government rescue package might result in a change in sentiment in financial mark...
|
Professional Website Design For Corporate - Get a Free Quote Today
Partners   
|
© 2008 The Ibtimes Company. All Rights Reserved. Terms of service | Privacy Policy | Advertising | About Us | Contact Us | Archives
EMAIL
PRINT
RSS
SHARE
